



Select FDA-approved specialty medications

Reference product

Drug name /	FDA-Approved	Administration Route /	Dosages /	Prescription	Pharmacy
Manufacturer	Indication(s)	Concentration	Device Type	written for	to dispense
 Humira (adalimumab) Manufacturer: AbbVie Cordavis only available in high (citrate-free) 	 AS CD (6+) HS (12+) PJIA (2+) PsA PsO RA UC (5+) UV (2+) 	 SC injection: Self-administered Concentration: High (citrate-free) Low 	SC: • 80 mg/0.8 mL PEN • 40 mg/0.8 mL PEN • 40 mg/0.4 mL PEN • 40 mg/0.8 mL PFS • 40 mg/0.4 mL PFS • 20 mg/0.2 mL PFS • 10 mg/0.1 mL PFS	Humira or adalimumab	Humira

Drug name /	FDA-Approved	Administration Route /	Dosages /	Prescription	Pharmacy
Manufacturer	Indication(s)	Concentration	Device Type	written for	to dispense
 Adalimumab-aacf (unbranded version of Idacio) Manufacturer: Fresenius Kabi 	 AS CD (6+) HS PJIA (2+) PsA PsO RA UC UV 	 SC injection: Self-administered Concentration: Low (citrate-free) 	SC: • 40 mg/0.8 mL PEN	Adalimumab-aacf	Adalimumab-aacf (unbranded) or Idacio (branded) depending on prescription benefit plan



Select FDA-approved specialty medications

Drug name / Manufacturer	FDA-Approved Indication(s)	Administration Route / Concentration	Dosages / Device Type	Prescription written for	Pharmacy to dispense
Adalimumab-aaty (unbranded version of Yuflyma) Manufacturer: • Celltrion	 AS CD (6+) HS PJIA (2+) PsA PsO RA UC 	SC injection: • Self-administered Concentration: • High (citrate-free)	SC: • 80 mg/0.8 mL PEN • 40 mg/0.4 mL PEN • 40 mg/0.4 mL PFS • 20 mg/0.2 mL PFS	Adalimumab-aaty	Adalimumab-aaty (unbranded) or Yuflyma (branded) depending on prescription benefit plan
Adalimumab-adaz (unbranded version of Hyrimoz) Manufacturer: • Sandoz	 AS CD (6+) HS PJIA (2+) PsA PsO RA UC UV 	 SC injection: Self-administered Concentration: High (citrate-free) 	SC: • 40 mg/0.4 mL PEN • 40 mg/0.4 mL PFS • 40 mg/0.8 mL PEN • 40 mg/0.8 mL PFS	Adalimumab-adaz	Adalimumab-adaz (unbranded) or Hyrimoz (branded) depending on prescription benefit plan
Adalimumab-fkjp (unbranded version of Hulio) Manufacturer: • Mylan	 AS CD (6+) HS PJIA (2+) PsA PsO RA UC UV 	 SC injection: Self-administered Concentration: Low (citrate-free) 	SC: • 40 mg/0.8 mL PEN • 40 mg/0.8 mL PFS • 20 mg/0.4 mL PFS	Adalimumab-fkjp	Adalimumab-fkjp (unbranded) or Hulio (branded) depending on prescription benefit plan



Select FDA-approved specialty medications

Drug name / Manufacturer	FDA-Approved Indication(s)	Administration Route / Concentration	Dosages / Device Type	Prescription written for	Pharmacy to dispense
Amjevita (adalimumab-atto) Manufacturer: • Amgen	 AS CD (6+) HS PJIA (2+) PsA PsO RA UC UV 	 SC injection: Self-administered Concentration: High (citrate-free) Low (citrate-free) 	SC: • 40 mg/0.8 mL PEN • 40 mg/0.8 mL PFS • 20 mg/0.4 mL PFS • 10 mg/0.2 mL PFS	Amjevita or adalimumab-atto	Amjevita
Hadlima (adalimumab-bwwd) Manufacturers: • Organon • Samsung Bioepis	 AS CD (6+) HS PJIA (2+) PsA PsO RA UC UV 	 SC injection: Self-administered Concentration: High (citrate-free) Low 	SC: • 40 mg/0.8 mL PFS • 40 mg/0.4 mL PFS • 40 mg/0.8 mL PEN • 40 mg/0.4 mL PEN	Hadlima or adalimumab-bwwd	Hadlima
Hulio (adalimumab-fkjp) Manufacturer: • Biocon Biologics	 AS CD (6+) HS PJIA (2+) PsA PsO RA UC UV 	 SC injection: Self-administered Concentration: Low (citrate-free) 	SC: • 40 mg/0.8 mL PEN • 40 mg/0.8 mL PFS • 20 mg/0.4 mL PFS	Hulio or adalimumab-fkjp	Hulio (brand) or adalimumab-fkjp (unbranded) dispensed based on prescription benefits plan



Select FDA-approved specialty medications

Drug name / Manufacturer	FDA-Approved Indication(s)	Administration Route / Concentration	Dosages / Device Type	Prescription written for	Pharmacy to dispense
Hyrimoz (adalimumab-adaz) Manufacturers: • Cordavis • Sandoz	 AS CD (6+) HS PJIA (2+) PsA PsO RA UC UV 	 SC injection: Self-administered Concentration: High (citrate-free) 	SC: • 80 mg/0.8 mL PEN • 40 mg/0.4 mL PEN • 80 mg/0.8 mL PFS • 40 mg/0.4 mL PFS • 20 mg/0.2 mL PFS • 10 mg/ 0.1 mL PFS	Hyrimoz or adalimumab-adaz	Hyrimoz (brand) or adalimumab-adaz (unbranded) dispensed based on prescription benefits plan
Idacio (adalimumab-aacf) Manufacturer: • Fresenius Kabi	 AS CD (6+) HS PJIA (2+) PsA PsO RA UC UV 	 SC injection: Self-administered Concentration: Low (citrate-free) 	SC: • 40 mg/0.8 mL PEN • 40 mg/0.8 mL PFS	Idacio or adalimumab-aacf	Idacio (brand) or adalimumab-aacf (unbranded) dispensed based on prescription benefits plan
Simlandi (adalimumab-ryvk) Manufacturer: • Alvotech/Teva	 AS CD (6+) HS PJIA (2+) PsA PsO RA UC UV 	 SC injection: Self-administered Concentration: High (citrate-free) 	SC: • 40 mg/0.4 mL PEN	Simlandi or adalimumab-ryvk	Simlandi



Select FDA-approved specialty medications

Available biosimilars

Drug name /	FDA-Approved	Administration Route /	Dosages /	Prescription	Pharmacy
Manufacturer	Indication(s)	Concentration	Device Type	written for	to dispense
Yuflyma (adalimumab-aaty) Manufacturer: • Celltrion	 AS CD (6+) HS PJIA (2+) PsA PsO RA UC UV 	 SC injection: Self-administered Concentration: High (citrate-free) 	SC: • 40 mg/0.4 mL PFS • 40 mg/0.4 mL PEN • 80 mg/0.8 mL PEN	Yuflyma or adalimumab-aaty	Yuflyma

Low Concentration 50mg/mL concentration (ex: 40mg/0.8mL); High Concentration 100 mg/mL concentration (ex: 40 mg/0.4 mL)

Select common adverse reactions include infections (e.g., upper respiratory, sinusitis), injection site reactions, headache and rash.

Biosimilars come in branded and unbranded products. Since branded and unbranded biosimilars share the same biologics license application (BLA), they may be changed with the corresponding unbranded or branded biosimilar as deemed by the prescription benefit plan.

Due to patent exclusivity (subject to change), biosimilars for Humira are not yet approved for these indications: Hidradenitis suppurativa in pediatrics 12–17 years; Uveitis in pediatrics aged 2 and older; and Ulcerative colitis in pediatrics 5–17 years.

FDA (U.S. Food and Drug Administration). SC (Subcutaneous). PFS (Prefilled syringe). AS (Ankylosing spondylitis). CD (Crohn's disease). HS (Hidradenitis Suppurativa). PJIA (Polyarticular juvenile idiopathic arthritis). PsA (Psoriatic arthritis). PsO (Plaque psoriasis). RA (Rheumatoid arthritis). UC (Ulcerative colitis). UV (Uveitis).

The information contained in this communication is provided in summary form. It is not intended for use as the sole basis of clinical treatment, as a substitute for reading the original research, nor as a substitute for the knowledge, skill, and judgment of the medical provider. This list is subject to change. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Specialty.

©2024 CVS Specialty. All rights reserved. 75-60438A 071524 🛞